近三年科研成果

SCI

[1] Jiang S#, Wang B#, Zhang M, Liu Z, Xiao Z, Gong J, Wang X, Zhang Z, Zhang Z. Quality of Life after Lung Cancer Surgery: sublobar resection versus lobectomy. BMC Surgery. 2023;23(1):353. doi: 10.1186/s12893-023-02259-1.

[2] Wang B, Wu M, Jia C, Zhao S, Sun S, Lan Y, Lu X, Zhang Z. PAR2 promotes malignancy of lung adenocarcinoma. Plos One. Under review.

[3] Zhao, H., Yang, K., Lan, Y., Wu, M., Wang, L., Cai, C., Lv, P., Sun, W., Lu, X., & Wang, B. (2025). Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma. Discover oncology, 16(1), 1168. https://doi.org/10.1007/s12672-025-03000-5

[4] Wang, L., Yang, K., Zhao, H., Lv, P., Cai, C., Wang, Z., & Wang, B. (2025). Real-world safety of carboplatin in non-small cell lung cancer: a retrospective signal detection and subgroup analysis based on the FAERS database. Frontiers in medicine, 12, 1590738. https://doi.org/10.3389/fmed.2025.1590738

[5] Yang, K., Zhao, H., Wang, L., Cai, C., Lv, P., & Wang, B. (2025). Correlation between allergic diseases and lung cancer: a systematic review and meta-analysis. Frontiers in medicine, 12, 1560000. https://doi.org/10.3389/fmed.2025.1560000

[6]Yang K, Sun W, Wang B. PSMA-TTV as a point-of-care selector. Lancet Oncol. 2025;26(11):e571. doi:10.1016/S1470-2045(25)00528-5

[7]Zhao Q, Yang K, Sun W, Li X, Gong B, Wang B. Pressure Injury Prevention: An Implementation Gap or a Documentation Chasm?. J Adv Nurs. Published online September 8, 2025. doi:10.1111/jan.70218

[8]Yang K, Sun W, Wang B. Individualized hemodynamic goals in major surgery: Is preoperative baseline the optimal target?. J Clin Anesth. 2025;106:111962. doi:10.1016/j.jclinane.2025.111962

[9]Zhao H, Yang K, Wang Z, et al. Comparable or Indeterminate? A Critical Appraisal of Efficacy Claims in the MARIPOSA Exploratory Analysis. J Thorac Oncol. 2025;20(12):e141-e142. doi:10.1016/j.jtho.2025.07.014

[10]Yang K, Sun W, Wang B. PSMA-TTV as a point-of-care selector. Lancet Oncol. 2025;26(11):e571. doi:10.1016/S1470-2045(25)00528-5

[11]Wang L, Wang Z, Lv P, Yang K, Wang B. Balancing Aesthetic Perfection and Oncological Pragmatism in Transareolar Thoracoscopic Surgery. ANZ J Surg. Published online December 19, 2025. doi:10.1111/ans.70447

[12]Wang L, Zhao H, Yang K, et al. Assessing the real-world safety of docetaxel for non-small cell lung cancer: Insights from a comprehensive analysis of FAERS data. PLoS One. 2025;20(9):e0331979. Published 2025 Sep 12. doi:10.1371/journal.pone.0331979

[13]Yang K, Wang L, Wang Z, Lv P, Cai C, Zhao H, Sun W, Wang B. Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. Front Immunol. 2026 Jan 28;17:1752298. doi: 10.3389/fimmu.2026.1752298. PMID: 41685302; PMCID: PMC12891178.

[14]Yang K, Sun W, Wang B. Commentary: Immuno-inflammatory signature for predicting therapeutic response and survival after stereotactic radiosurgery in NSCLC patients with brain metastases: a retrospective cohort study. Front Immunol. 2026;17:1782399. Published 2026 Feb 6. doi:10.3389/fimmu.2026.1782399

[15]Yang K, Sun W, Wang B. Commentary: Immuno-inflammatory signature for predicting therapeutic response and survival after stereotactic radiosurgery in NSCLC patients with brain metastases: a retrospective cohort study. Front Immunol. 2026 Feb 6;17:1782399. doi: 10.3389/fimmu.2026.1782399. PMID: 41727471; PMCID: PMC12920427.

[16]Yang K, Wang L, Wang Z, Lv P, Cai C, Zhao H, Sun W, Wang B. Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects. Front Immunol. 2026 Jan 28;17:1752298. doi: 10.3389/fimmu.2026.1752298. PMID: 41685302; PMCID: PMC12891178.

北大核心

[1] 王哲,王雷,赵晖,吕佩昀,蔡承伦,杨坤鹏 & 王宝.(2025).顺铂治疗非小细胞肺癌的真实世界安全性：基于FAERS数据库的药物警戒分析及外部验证.药物评价研究,48(09),2603-2616.https://doi.org/CNKI:SUN:YWPJ.0.2025-09-020.

[2] 王宝,孙诗卓,杨坤鹏,兰月娇 & 芦小单.(2024).老年非小细胞肺癌患者PAR2基因表达与其预后的相关性.中国老年学杂志,44(17),4116-4119.https://doi.org/CNKI:SUN:ZLXZ.0.2024-17-006.

[3]赵晖,杨坤鹏,王雷,王宝.PAR2在肺腺癌中表达特征及其临床意义：基于TCGA数据库的多维度分析[J].中国老年学杂志,2025,45(24):5929-5937.